Basic Information
| LncRNA/CircRNA Name | LINC01296 |
| Synonyms | DUXAP9, LINC01296, FLJ39632, lncRNA-CTD903 |
| Region | GRCh38_14:19062316-19131167 |
| Ensemble | ENSG00000225210 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | 5-FU | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | CRC tissues, human CRC cell lines SW620, SW480, HCT-8, 5-FU-resistant HCT-8 cells (HCT-8/5-FU) and LoVo |
| Expression Pattern | differential expression |
| Function Description | Differential expression of linc01296 is confirmed and closely correlated with the malignancy of CRC cell lines and poor clinical prognosis. Moreover, alteration of linc01296 affects CRC cell proliferation, metastasis and chemoresistance to 5-fluorouracil (5-FU) in vitro. Mechanically, linc01296 acts as a direct target of miR-26a, and thereby influenced CRC malignancy. Our investigation corroborates that linc01296 functions as an endogenous sponge of miR-26a to regulate mucin1 (MUC1) expression, catalyzed by GALNT3, which modulates the activity of PI3K/AKT pathway. Interestingly, upregulated linc01296 promotes the tumorigensis, liver metastasis and chemoresistance of CRC cell lines in vivo. |
| Pubmed ID | 30547804 |
| Year | 2018 |
| Title | LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway |
External Links
| Links for LINC01296 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |